Selank
Tuftsin Analog Heptapeptide
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
Selank's human evidence rests almost entirely on small Russian comparative and open trials in generalized anxiety disorder and neurasthenia (Zozulia, Neznamov and colleagues, reported around 2008 in Zhurnal Nevrologii i Psikhiatrii), which describe an anxiolytic signal comparable to low-dose benzodiazepines without sedation but were modest in size and are not independently replicated outside Russia. No Western randomized controlled trial has been completed, and most mechanistic work (GABA-A receptor modulation, BDNF, monoamine effects) is preclinical, so the honest grade is preliminary human evidence rather than mixed or moderate RCT support.
- FDA
- Not approved (USA). Registered in Russia in 2009 for generalized anxiety disorder. Selank acetate (TP-7) was removed from FDA Category 2 of the interim 503A compounding list on September 20, 2024 after the nominator withdrew, and it is not on the approved 503A bulks list.
- WADA
- Not on the WADA Prohibited List
Reference only. Not medical advice.
What can go wrong
No completed Western trial; the human evidence base is small, Russian, and not independently replicated. Sold in the US as a research chemical, not for human consumption, and not eligible for pharmacy compounding under 503A.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Selank. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
A synthetic heptapeptide based on tuftsin, a peptide naturally produced by the spleen, discovered by Victor Najjar at Tufts in 1970 (hence the name). Registered in Russia since 2009 for anxiety disorders, with completed Phase III Russian trials. Zero Western clinical trials.
Built on a spleen peptide. Anxiety off, without sedation. No Western trial has ever been run.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Combinations named above are how people use these compounds together, under names the community gave them. The combinations themselves have not been studied. Evidence for one compound is not evidence for a pair.
How it is supposed to work
Selank is a calming peptide built from tuftsin, a natural immune-regulating fragment of an antibody. Its main effect is anxiolytic: in Russian research it reduces anxiety by acting as a positive modulator of GABA, the brain’s primary calming system, but, unlike benzodiazepines, without causing sedation or dependence. It also enhances serotonin signaling and, reflecting its immune origin, modulates the immune system by shifting interferon and cytokine activity. Like Semax, it is given as a nasal spray for rapid brain access.
Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, an analog of the natural immunopeptide tuftsin (a four-amino-acid fragment of an antibody produced in the spleen), extended with the same Pro-Gly-Pro tail used in Semax to make it stable enough to act as a drug. It was developed at the same Russian institute as Semax, which is why the two share an origin, a stabilizing strategy and an intranasal route despite doing opposite things.
- Type
- Tuftsin analog
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Acts on
- GABA (anxiolytic)
- Also
- Immunomodulatory
- Russia
- Registered drug
- FDA
- Not approved
Calm Without Dependence, On Russian Data
Selank’s appeal points straight at a real unmet need, which is exactly why it deserves a careful look. Benzodiazepines work for anxiety but bring sedation, cognitive dulling, tolerance and dependence; a drug that calmed anxiety without that baggage would be genuinely valuable. Russian studies report that Selank does just that, reducing anxiety comparably to benzodiazepines while leaving alertness intact and without dependence, plus an unusual immune-modulating effect on the side. The catch is the same one that shadows its sister peptide: the clinical evidence, in generalized anxiety and a condition the Russians call neurasthenia, is almost entirely Russian, from a single tradition, and not replicated in large Western trials. So a genuinely attractive claim, a benzo-like calm without the downsides, rests on an evidence base Western medicine has not independently confirmed.
Safety in detail
Russian reports describe Selank as generally well tolerated at intranasal doses used in their anxiety studies, with no sedation or dependence signal noted, but long-term safety and off-label use have not been evaluated in independent Western studies.
- Its headline safety advantage, reported in Russian studies, is anxiety relief without the sedation, cognitive impairment or dependence of benzodiazepines.
- Generally well tolerated intranasally, with mild and infrequent side effects reported.
- Long-term safety data and independent Western evaluation are limited.
- Outside Russia most material is gray-market research-use-only, with the usual unverified identity, dose and purity risks.
- It is a registered medicine in Russia but not FDA-approved, and is sold as a research compound in the US.
- It is not specifically listed on the WADA Prohibited List, though athletes should check the current code.
Children and teenagers
As with Semax, Selank has some clinical history within the Russian medical system, but its use in minors outside that system has no Western oversight, no independent safety validation, and the usual gray-market sourcing risks. Anxiety in children and adolescents should be addressed by qualified professionals, not with self-sourced research peptides, and any pediatric use should occur only under proper medical care.
What people get wrong
Often saidIt is a proven benzo alternative
ActuallyIt is registered in Russia for anxiety, but no Western RCT has compared it head-to-head with anything.
Often saidSpleen origin makes it exotic and risky
ActuallyThe spleen-brain link is real biology, tuftsin is genuinely spleen-derived, but that does not by itself make Selank either safe or dangerous; it is simply understudied in the West.
Who profits, and who pushes back
Western psychiatric community
Every published Selank trial was run in Russia by institutions tied to its development.
FDA / DEA status
Neither approved nor scheduled in the US. Absence of scheduling is not a safety assessment.
Nootropics community
Devoted following for anxiolytic effects without sedation. No mainstream influencer endorsement identified.
Functional-medicine physicians
Some advocate it as a benzodiazepine alternative; prescribing clinics may have revenue interests.
Like Semax, Selank is a registered pharmaceutical in Russia, manufactured and sold there, giving it a legitimate commercial base at home. Abroad, the money runs through the gray-market and nootropic-community economy: research-peptide vendors and nasal-spray sellers serving people seeking anxiety relief or cognitive balance. Its dual status, approved drug in Russia and research chemical elsewhere, defines both its supply and how it is marketed.
Where the research comes from
Most of the published research on this comes from one place. 92% of it is from Russia. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Russia | 92% |
| Other | 8% |
Research published from: Russia.
How we got here
Selank is a synthetic heptapeptide analog of the endogenous immune peptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tail for metabolic stability. It was developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as an anxiolytic and nootropic. In the West it circulates chiefly as a research chemical and intranasal preparation.
Selank was developed at the same Moscow institute as Semax, engineered from the natural immunopeptide tuftsin with a Pro-Gly-Pro tail to make it stable. Russian research through the 1990s and 2000s built its case as a non-sedating, non-addictive anxiolytic with an unusual immune-modulating side, leading to its registration as a pharmaceutical in Russia. Like Semax, it then spread internationally as a gray-market nootropic and anxiety aid, carried by the biohacking community while its Russian evidence base went untested in the West.
- 1980s-1990sRussian researchers engineer Selank from tuftsin with a stabilizing Pro-Gly-Pro tail.
- 2000sRussian clinical studies report anxiety relief comparable to benzodiazepines without dependence.
- 2000sSelank is registered as a pharmaceutical in Russia.
- 2010s-2020sAdopted internationally as a gray-market anxiolytic and nootropic, still without Western trials.
The numbers behind the grade
- Type
- Tuftsin analog
- Mechanism
- GABA modulation (anxiolytic)
- Russia
- Registered drug
- FDA
- Not approved
- Route
- Intranasal
- Western RCTs
- None large
The people taking it
One of the two most famous Russian nootropic peptides and the calming half of the Semax-and-Selank stack, notable for the appealing claim of benzodiazepine-like relief without dependence.
In Russia, Selank is used clinically for anxiety and related conditions across a general adult population. Abroad, it is used by people seeking anxiety and stress relief without benzodiazepine dependence, by biohackers, and by nootropic users pairing it with Semax. As with all gray-market use, there is no reliable demographic data outside the Russian clinical setting.
Registered and used in Russia as an anxiolytic, and used worldwide gray-market for anxiety and stress without benzodiazepine dependence. Its standing rests on an attractive profile reported in Russian studies but not replicated in the West.
Set against the alternatives
The comparison that matters most is to benzodiazepines: Selank claims their anxiety relief without the sedation, tolerance and dependence that make benzodiazepines a problem, which, if confirmed, would be a meaningful advance, but the claim is unreplicated outside Russia. Against its sister peptide Semax, the two are complementary opposites, Selank calming and Semax activating, and the most popular Russian nootropic stack pairs them. Against Western anxiety treatments like SSRIs or buspirone, Selank’s reported rapid, non-sedating action is appealing but lacks the large-trial backing those drugs have. Its promise is the profile; its limitation is the unvetted evidence.
What we do not know
- Whether large independent Western trials would confirm benzodiazepine-comparable anxiety relief without sedation or dependence.
- Whether its immunomodulatory effects have any clinical relevance.
- What its long-term safety profile is by independent evaluation.
- Why a potentially non-addictive anxiolytic has not been pursued for Western development.
What could change
Non-addictive anxiolytic interestThe need for safe anxiety drugs could draw independent study of its benzodiazepine-alternative claim.ImmunomodulationIts tuftsin-derived immune effects are a distinct, under-explored angle.Independent trialsLarge Western trials would be the decisive step in vetting its profile.The Semax-Selank stackContinued popularity as the calming half of the Russian nootropic pairing.
Legal status
Selank is a registered pharmaceutical in Russia, approved there as an anxiolytic for generalized anxiety and related conditions. It is not FDA-approved and is sold in the US and much of the West as a research-use-only compound, commonly as a nasal spray. Its legitimacy, like Semax’s, depends entirely on jurisdiction.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
In Russia, available as an approved medicine through pharmacies. Abroad, available only as research-use-only material and nasal sprays from peptide and nootropic vendors, which is not an approved medical route; for genuine anxiety, professional care is the appropriate path, and any gray-market use should at least involve third-party-tested product.
Inexpensive in Russia as an approved drug, and modestly priced abroad as a research peptide or nasal spray. The low cost outside Russia comes without assurance of identity, dose or purity, so independent testing matters.
Material comes from Russian pharmaceutical manufacturing for the domestic drug and, for the gray market abroad, from Chinese synthesis sold as research compound, with very different levels of oversight and a certificate of analysis the only check on the latter.
Russia (registered drug)Manufactured and sold as an approved anxiolytic, the most controlled source.China and research vendorsThe dominant source of gray-market Selank abroad, as research-use-only material and nasal sprays.Nootropic and anxiety community channelOnline vendors serving stress- and anxiety-focused users distribute much of the Western supply.
At a glance
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Parent
- Tuftsin (spleen peptide)
- Targets
- GABA / serotonin systems
- Russia status
- Registered 2009
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Selank.
Nothing outstanding on this one.
Sources
Selank is a synthetic heptapeptide analog of tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics, Russian Academy of Sciences, and registered in Russia for generalized anxiety disorder
Russian comparative trial reporting rapid and slow responder patterns during treatment of generalized anxiety disorder with the peptide anxiolytic Selank
Efficacy and possible mechanisms of action of the peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (Russian clinical report)
Selank alters expression of GABA-A receptor subunit, transporter, and metabolizing genes in IMR-32 neuroblastoma cells, supporting a GABAergic mechanism (preclinical, in vitro)
Review of the molecular aspects of heptapeptide Selank biological activity, describing it as an approved Russian anxiolytic with efficacy comparable to low-dose benzodiazepines and positive allosteric modulation of GABA receptors
Selank enhances the anxiolytic effect of diazepam in unpredictable chronic mild stress in rats (preclinical animal model)
Selank, a tuftsin analog, attenuates aversive signs of morphine withdrawal in rats, reducing the withdrawal index by about 39.6 percent, slightly inferior to diazepam (preclinical)
Selank protects against ethanol-induced memory impairment by regulating BDNF content in the hippocampus and prefrontal cortex in rats (preclinical neurotrophic mechanism)
Selank is not FDA approved and is sold in the United States as a research chemical, not for human consumption, pending FDA determination
FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
Selank acetate (TP-7) was removed from Category 2 of the interim 503A bulks list on September 20, 2024 based on nominator withdrawal, and is not on the approved 503A bulks list, so compounding pharmacies may not compound it
The studies that matter
Zozulia et al2008
A Russian clinical study reported Selank effective in generalized anxiety disorder and neurasthenia, with anxiety reduction comparable to benzodiazepines but without sedation or dependence.
Vyunova; Filatova2017-2018
Mechanistic work characterized Selank as a positive allosteric modulator of GABA binding, the basis of its anxiolytic effect.
Semenova; Ershov2009
Studies showed Selank enhances brain serotonin metabolism and, reflecting its tuftsin origin, modulates immune signaling such as interferon and cytokine activity.
Panikratova et al, fMRI2020
A human imaging study contrasted Selank and Semax and found distinguishable effects on brain connectivity.
Western randomized trialsnone large
No large independent Western RCT of Selank exists, so the anxiolytic claims rest on the Russian evidence base.